The Food and Drug Administration is preparing to evaluate seven unapproved peptide substances that have become increasingly popular for claims tied to weight loss, healing, and longevity.

The FDA’s Pharmacy Compounding Advisory Committee will meet on July 23 and 24 at the agency’s White Oak Campus in Silver Spring, Maryland, to review whether any of the peptides should be added to the 503A Bulks List. That designation would permit their limited use in compounded prescription drugs made by state-licensed pharmacies.

Although the peptides have not received federal approval, they are already widely obtainable through wellness centers, compounders, and a growing number of online vendors operating in a gray market.

Health and Human Services Secretary Robert F. Kennedy Jr. has publicly supported expanding access to certain peptide treatments, while FDA scientists have voiced reservations about inadequate trial data on safety and efficacy.

Here's What They're Not Telling You About Your Retirement

Reuters has reported that demand for peptides is expected to remain strong regardless of the regulatory outcome as people seek them for purposes ranging from weight management and muscle growth to chronic pain and wound repair.

FDA briefing materials outline multiple proposed delivery forms under consideration, including capsules, injections, nasal sprays, creams, and suppositories. The review covers peptide candidates linked to uses such as wound recovery, inflammatory conditions, cerebral ischemia, migraine, trigeminal neuralgia, opioid withdrawal, chronic insomnia, and narcolepsy.

Indiana-based urologist Dr. Alex Tatem, a performance medicine and peptide specialist, is scheduled to testify at the hearings. He argues that years of use by patients demonstrate reassuring safety outcomes for the substances being reviewed.

Tatem told Fox News Digital that compounds such as BPC-157 and TB-500 have aided healing from injuries with strong safety profiles when compared to common over-the-counter pain relievers like ibuprofen. He pointed out that while ibuprofen is federally approved, the FDA itself warns of potentially serious side effects including gastrointestinal bleeding and cardiovascular risks.

This Could Be the Most Important Video Gun Owners Watch All Year

According to Tatem, millions of doses of BPC-157 have been administered worldwide with very few adverse reports. He described peptides as “natural substances that our bodies make and are familiar with,” which he said contributes to their safety record.

The FDA has countered that similarity to naturally occurring compounds does not necessarily ensure safety or effectiveness. Agency reviewers emphasize that robust human clinical trials are still lacking.

Fox News medical analyst Dr. Marc Siegel agreed that peptide safety requires further study. He said, “I am not convinced the data is fully there yet,” noting that Kennedy had previously commented to him that some peptides may be beneficial while others need stricter evaluation.

Tatem acknowledged that the upcoming discussions could be contentious. However, he expressed hope that the committee will weigh what he called real-world experience from tens of millions of administered doses between 2014 and 2023, which he said showed adverse event rates “well under 0.1%.”

Even if the panel recommends inclusion, the FDA would still need to undertake a full review and rulemaking process before placing any peptides on the official bulk compounding list. That list determines which active ingredients pharmacies may legally use in customized prescriptions.

Tatem also suggested the FDA could allow temporary, more flexible enforcement while final decisions are pending, though the agency has not stated any plan to do so.

Looking ahead, Tatem said he hopes that by late in the year doctors — including telehealth providers — will be able to prescribe peptide therapies under medical supervision.

He encouraged patients who support access to contact their local lawmakers to advocate for “safe, regulated peptides made in the United States.”